Viridian Therapeutics, (id:5271 VRDN)
20.20 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 11:36:57 AM)
Exchange closed, opens in 1 day 21 hours
About Viridian Therapeutics,
Market Capitalization 1.60B
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease. In addition, the company offers VRDN-006 and VRDN-008 a preclinical program for autoimmune disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021.Viridian Therapeutics, Inc. was founded in 2010 and is headquartered in Waltham, Massachusetts.
| Headquarters (address) |
221 Crescent Street Waltham 02453 MA United States |
| Phone | 617 272 4600 |
| Website | https://www.viridiantherapeutics.com |
| Employees | 94 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | VRDN |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 11.40 - 27.20 |
| Market Capitalization | 1.60B |
| P/E trailing | -3.80 |
| P/E forward | -4.82 |
| Price/Sale | 5,282.60 |
| Price/Book | 3.07 |
| Beta | 1.11 |
| EPS | -4.32 |
| EPS United States (ID:6, base:3400) | 24.26 |